Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

BACKGROUND: Insulin degludec (IDeg) is a neutral, ultralong-acting new generation basal insulin analog developed by NovoNordisk currently in Phase III clinical development. IDeg offers a duration of action of more than 42 hours in adults, much longer than current basal insulin formulations. OBJECTIV...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fei, Surh, Justine, Kaur, Manmeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402007/
https://www.ncbi.nlm.nih.gov/pubmed/22826637
http://dx.doi.org/10.2147/DMSO.S21979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402007/
https://www.ncbi.nlm.nih.gov/pubmed/22826637
http://dx.doi.org/10.2147/DMSO.S21979

Ejemplares similares